|
pubmed:abstractText |
Sulphadoxine-pyrimethamine has been abandoned as first- or second-line treatment by most African malaria endemic countries in favour of artemisinin-based combination treatments, but the drug is still used as intermittent preventive treatment during pregnancy. However, resistance to sulphadoxine-pyrimethamine has been increasing in the past few years and, although the link between molecular markers and treatment failure has not been firmly established, at least for pregnant women, it is important to monitor such markers.
|
|
pubmed:affiliation |
Prince Leopold Institute of Tropical Medicine, Department of Parasitology, Nationalestraat 155, B2000, Antwerp, Belgium. p.mens@kit.nl
|
